Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized Double Masked Parallel Design Exploratory Study to Assess Safety and Efficacy of Two Different Doses of Intravitreal Anti-VEGF Treatment With Ranibizumab (0.12 mg vs. 0.20 mg) in Infants With Retinopathy of Prematurity (ROP)

NCT02134457 is registered in ClinicalTrials.gov with University Hospital Freiburg as lead sponsor.

NCT NCT02134457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02134457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized Double Masked Parallel Design Exploratory Study to Assess Safety and Efficacy of Two Different Doses of Intravitreal Anti-VEGF Treatment With Ranibizumab (0.12 mg vs. 0.20 mg) in Infants With Retinopathy of Prematurity (ROP)
Lead sponsor
University Hospital Freiburg
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2014
Completion date
January 31, 2017
Enrollment
19 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

retinopathy of prematurity (rop)